Multicenter phase 1-2 trial of upfront venetoclax plus quizartinib with low-dose cytarabine or azacitidine for AML in older unfit patients

Many older patients with acute myeloid leukemia (AML) are ineligible for intensive chemotherapy. Quizartinib is an oral, selective, FMS-like tyrosine kinase 3 (FLT3) inhibitor. The multicenter phase 1-2 VEN-A-QUI trial in Spain evaluated quizartinib in combination with either azacitidine (VEN-AZA-Quiz) or low-dose cytarabine (VEN-LDAC-Quiz) for newly diagnosed FTL3-ITD-positive or negative AML in patients aged ≥ 60 years ineligible for intensive chemotherapy. In phase 1, 14 patients were assigned to parellel VEN-AZA-Quiz or VEN-LDAC-Quiz. The quizartinib recommended phase 2 dose was 60 mg/day for VEN-AZA-Quiz and 40 mg/day for VEN-LDAC-Quiz, In phase 2, 60 patients were randomized 1:1 to VEN-AZA-Quiz (n=31) or VEN-LDAC-Quiz (n=29). The primary endpoint of phase 2 was composite complete remission (CRc). CRc by cycle 4 was achieved in 18/31 (58.1%) patients receiving VEN-AZA-Quiz and 15/29 (51.7%) patients receiving VEN-LDAC-Quiz (p=0.80), with median overall survival (OS) 16.9 months and 8.9 months (p=0.81) and 3-year OS rates 22.6% and 27.6%. Overall, a high CRc rate (10/13; 76.9%) and median OS (29.3%) was observed in FLT3-ITD-positive patients. Median OS was 32 months for de novo AML and 7.5 months for secondary AML. The most common adverse events were infectious and hematologic toxicity. The authors conclude that both regimens demonstrated clinical activity for newly diagnosed AML in patients ineligible for intensive chemotherapy, particularly in patients with de novo AML, with an acceptable safety profile.